Cover Image

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of...

Full description

Saved in:
Bibliographic Details
Main Authors: Lieverse, Relinde I. Y. (Author) , Van Limbergen, Evert J. (Author) , Oberije, Cary J. G. (Author) , Troost, Esther G. C. (Author) , Hadrup, Sine R. (Author) , Dingemans, Anne-Marie C. (Author) , Hendriks, Lizza E. L. (Author) , Eckert, Franziska (Author) , Hiley, Crispin (Author) , Dooms, Christophe (Author) , Lievens, Yolande (Author) , de Jong, Monique C. (Author) , Bussink, Johan (Author) , Geets, Xavier (Author) , Valentini, Vincenzo (Author) , Elia, Giuliano (Author) , Neri, Dario (Author) , Billiet, Charlotte (Author) , Abdollahi, Amir (Author) , Pasquier, David (Author) , Boisselier, Pierre (Author) , Yaromina, Ala (Author) , De Ruysscher, Dirk (Author) , Dubois, Ludwig J. (Author) , Lambin, Philippe (Author)
Format: Article (Journal)
Language:English
Published: 15 June 2020
In: BMC cancer
Year: 2020, Volume: 20
ISSN:1471-2407
DOI:10.1186/s12885-020-07055-1
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-020-07055-1
Get full text
Author Notes:Relinde I.Y. Lieverse, Evert J. Van Limbergen, Cary J.G. Oberije, Esther G.C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E.L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois and Philippe Lambin

MARC

LEADER 00000caa a2200000 c 4500
001 1733236708
003 DE-627
005 20230427150627.0
007 cr uuu---uuuuu
008 200917s2020 xx |||||o 00| ||eng c
024 7 |a 10.1186/s12885-020-07055-1  |2 doi 
035 |a (DE-627)1733236708 
035 |a (DE-599)KXP1733236708 
035 |a (OCoLC)1341360609 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Lieverse, Relinde I. Y.  |e VerfasserIn  |0 (DE-588)1217818383  |0 (DE-627)1733239472  |4 aut 
245 1 0 |a Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR  |b a multicentre, randomised controlled open-label phase II trial  |c Relinde I.Y. Lieverse, Evert J. Van Limbergen, Cary J.G. Oberije, Esther G.C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E.L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois and Philippe Lambin 
264 1 |c 15 June 2020 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 17.09.2020 
520 |a About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR). 
700 1 |a Van Limbergen, Evert J.  |e VerfasserIn  |4 aut 
700 1 |a Oberije, Cary J. G.  |e VerfasserIn  |4 aut 
700 1 |a Troost, Esther G. C.  |e VerfasserIn  |4 aut 
700 1 |a Hadrup, Sine R.  |e VerfasserIn  |4 aut 
700 1 |a Dingemans, Anne-Marie C.  |e VerfasserIn  |4 aut 
700 1 |a Hendriks, Lizza E. L.  |e VerfasserIn  |4 aut 
700 1 |a Eckert, Franziska  |e VerfasserIn  |4 aut 
700 1 |a Hiley, Crispin  |e VerfasserIn  |4 aut 
700 1 |a Dooms, Christophe  |e VerfasserIn  |4 aut 
700 1 |a Lievens, Yolande  |e VerfasserIn  |4 aut 
700 1 |a de Jong, Monique C.  |e VerfasserIn  |4 aut 
700 1 |a Bussink, Johan  |e VerfasserIn  |4 aut 
700 1 |a Geets, Xavier  |e VerfasserIn  |4 aut 
700 1 |a Valentini, Vincenzo  |e VerfasserIn  |4 aut 
700 1 |a Elia, Giuliano  |e VerfasserIn  |4 aut 
700 1 |a Neri, Dario  |e VerfasserIn  |4 aut 
700 1 |a Billiet, Charlotte  |e VerfasserIn  |4 aut 
700 1 |a Abdollahi, Amir  |e VerfasserIn  |0 (DE-588)129612715  |0 (DE-627)474757765  |0 (DE-576)297748874  |4 aut 
700 1 |a Pasquier, David  |e VerfasserIn  |4 aut 
700 1 |a Boisselier, Pierre  |e VerfasserIn  |4 aut 
700 1 |a Yaromina, Ala  |e VerfasserIn  |4 aut 
700 1 |a De Ruysscher, Dirk  |e VerfasserIn  |4 aut 
700 1 |a Dubois, Ludwig J.  |e VerfasserIn  |4 aut 
700 1 |a Lambin, Philippe  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t BMC cancer  |d London : BioMed Central, 2001  |g 20(2020) Artikel-Nummer 557, 10 Seiten  |h Online-Ressource  |w (DE-627)326643710  |w (DE-600)2041352-X  |w (DE-576)107014645  |x 1471-2407  |7 nnas  |a Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR a multicentre, randomised controlled open-label phase II trial 
773 1 8 |g volume:20  |g year:2020  |g extent:10  |a Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR a multicentre, randomised controlled open-label phase II trial 
856 4 0 |u https://doi.org/10.1186/s12885-020-07055-1  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200917 
993 |a Article 
994 |a 2020 
998 |g 129612715  |a Abdollahi, Amir  |m 129612715:Abdollahi, Amir  |d 910000  |d 911400  |e 910000PA129612715  |e 911400PA129612715  |k 0/910000/  |k 1/910000/911400/  |p 19 
999 |a KXP-PPN1733236708  |e 3757505883 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Relinde I.Y. Lieverse, Evert J. Van Limbergen, Cary J.G. Oberije, Esther G.C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E.L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois and Philippe Lambin"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["326643710"],"zdb":["2041352-X"],"issn":["1471-2407"]},"language":["eng"],"pubHistory":["1.2001 -"],"disp":"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR a multicentre, randomised controlled open-label phase II trialBMC cancer","origin":[{"dateIssuedKey":"2001","publisherPlace":"London ; Berlin ; Heidelberg","publisher":"BioMed Central ; Springer","dateIssuedDisp":"2001-"}],"recId":"326643710","title":[{"title_sort":"BMC cancer","title":"BMC cancer"}],"part":{"year":"2020","volume":"20","extent":"10","text":"20(2020) Artikel-Nummer 557, 10 Seiten"},"note":["Gesehen am 22.05.20"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"origin":[{"dateIssuedDisp":"15 June 2020","dateIssuedKey":"2020"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 17.09.2020"],"title":[{"title_sort":"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR","subtitle":"a multicentre, randomised controlled open-label phase II trial","title":"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR"}],"person":[{"display":"Lieverse, Relinde I. Y.","family":"Lieverse","roleDisplay":"VerfasserIn","given":"Relinde I. Y.","role":"aut"},{"display":"Van Limbergen, Evert J.","family":"Van Limbergen","roleDisplay":"VerfasserIn","role":"aut","given":"Evert J."},{"roleDisplay":"VerfasserIn","display":"Oberije, Cary J. G.","family":"Oberije","role":"aut","given":"Cary J. G."},{"roleDisplay":"VerfasserIn","family":"Troost","display":"Troost, Esther G. C.","role":"aut","given":"Esther G. C."},{"roleDisplay":"VerfasserIn","family":"Hadrup","display":"Hadrup, Sine R.","given":"Sine R.","role":"aut"},{"display":"Dingemans, Anne-Marie C.","family":"Dingemans","roleDisplay":"VerfasserIn","role":"aut","given":"Anne-Marie C."},{"given":"Lizza E. L.","role":"aut","family":"Hendriks","display":"Hendriks, Lizza E. L.","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Franziska","roleDisplay":"VerfasserIn","display":"Eckert, Franziska","family":"Eckert"},{"given":"Crispin","role":"aut","family":"Hiley","display":"Hiley, Crispin","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Dooms, Christophe","family":"Dooms","given":"Christophe","role":"aut"},{"role":"aut","given":"Yolande","roleDisplay":"VerfasserIn","family":"Lievens","display":"Lievens, Yolande"},{"display":"de Jong, Monique C.","family":"de Jong","roleDisplay":"VerfasserIn","role":"aut","given":"Monique C."},{"given":"Johan","role":"aut","display":"Bussink, Johan","family":"Bussink","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Geets","display":"Geets, Xavier","given":"Xavier","role":"aut"},{"role":"aut","given":"Vincenzo","family":"Valentini","display":"Valentini, Vincenzo","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Elia","display":"Elia, Giuliano","role":"aut","given":"Giuliano"},{"role":"aut","given":"Dario","family":"Neri","display":"Neri, Dario","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Charlotte","roleDisplay":"VerfasserIn","family":"Billiet","display":"Billiet, Charlotte"},{"role":"aut","given":"Amir","roleDisplay":"VerfasserIn","family":"Abdollahi","display":"Abdollahi, Amir"},{"role":"aut","given":"David","display":"Pasquier, David","family":"Pasquier","roleDisplay":"VerfasserIn"},{"given":"Pierre","role":"aut","roleDisplay":"VerfasserIn","display":"Boisselier, Pierre","family":"Boisselier"},{"roleDisplay":"VerfasserIn","display":"Yaromina, Ala","family":"Yaromina","role":"aut","given":"Ala"},{"given":"Dirk","role":"aut","roleDisplay":"VerfasserIn","display":"De Ruysscher, Dirk","family":"De Ruysscher"},{"family":"Dubois","display":"Dubois, Ludwig J.","roleDisplay":"VerfasserIn","given":"Ludwig J.","role":"aut"},{"given":"Philippe","role":"aut","family":"Lambin","display":"Lambin, Philippe","roleDisplay":"VerfasserIn"}],"recId":"1733236708","language":["eng"],"id":{"eki":["1733236708"],"doi":["10.1186/s12885-020-07055-1"]},"physDesc":[{"extent":"10 S."}]} 
SRT |a LIEVERSERESTEREOTACT1520 

Similar Items